Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Healthy Participants
Interventions: Brazikumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Heart Failure
Interventions: AZD3427, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more

Conditions: Meningioma
Interventions: AZD2014; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Healthy Participants
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions: AZD5991, AZD5991 + Venetoclax; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Orange, California • Aurora, Colorado • Atlanta, Georgia + 7 more

Conditions: Asthma
Interventions: Placebo, Brodalumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 73
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more

Conditions: Advanced Solid Tumours
Interventions: AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Advanced Solid Tumours
Interventions: Adavosertib, Itraconazole, Rifampicin, Omeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Portland, Oregon • Austin, Texas • Dallas, Texas

Conditions: Saphenous Vein Graft Disease
Interventions: Aspirin, Ticagrelor; Drug
Lead sponsor: Boca Raton Regional Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Oleclumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Anemia Associated With End Stage Renal Disease (ESRD)
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more

Conditions: Triple Negative Breast Cancer
Interventions: Olaparib Oral Product, Olaparib Oral Product in combination with Durvalumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

About this AstraZeneca sponsor directory page